| Literature DB >> 31919539 |
Arun Nanditha1,2, Hazel Thomson3, Priscilla Susairaj1, Weerachai Srivanichakorn3,4, Nick Oliver3, Ian F Godsland3, Azeem Majeed5, Ara Darzi6, Krishnamoorthy Satheesh1, Mary Simon1, Arun Raghavan1,2, Ramachandran Vinitha1,2, Chamukuttan Snehalatha1, Kate Westgate7, Soren Brage7, Stephen J Sharp7, Nicholas J Wareham8, Desmond G Johnston9, Ambady Ramachandran10,11.
Abstract
AIMS/HYPOTHESIS: This randomised controlled trial was performed in India and the UK in people with prediabetes to study whether mobile phone short message service (SMS) text messages can be used to motivate and educate people to follow lifestyle modifications, to prevent type 2 diabetes.Entities:
Keywords: Behavioural change; Diabetes prevention; Glycosylated haemoglobin A1c; Lifestyle modification; Mobile technology; Prediabetes; Screening; Short message service
Mesh:
Substances:
Year: 2020 PMID: 31919539 PMCID: PMC6997257 DOI: 10.1007/s00125-019-05061-y
Source DB: PubMed Journal: Diabetologia ISSN: 0012-186X Impact factor: 10.122
Fig. 1CONSORT diagram of trial profile. FPG, fasting plasma glucose
Baseline characteristics by randomised group
| Variable | Combined India and UK | India | UK | |||
|---|---|---|---|---|---|---|
| Control ( | Intervention ( | Control ( | Intervention ( | Control ( | Intervention ( | |
| Sex | ||||||
| Men | 661 (64.1%) | 658 (63.8%) | 445 (75.8%) | 442 (75.7%) | 216 (48.6%) | 216 (48.3%) |
| Women | 370 (35.9%) | 373 (36.2%) | 142 (24.2%) | 142 (24.3%) | 228 (51.4%) | 231 (51.7%) |
| Age (years) | 52.0 (10.2) | 52.1 (10.3) | 45.8 (5.4) | 45.8 (5.4) | 60.2 (9.3) | 60.3 (9.4) |
| Weight (kg) | 79.7 (15.6) | 79.0 (15.4) | 75.3 (10.8) | 74.7 (10.7) | 85.4 (18.9) | 84.5 (18.5) |
| BMI (kg/m2) | 28.9 (4.8) | 28.7 (4.7) | 27.9 (3.6) | 27.5 (3.3) | 30.2 (5.8) | 30.2 (5.7) |
| Waist circumference (cm) | 97.8 (11.3) | 97.5 (11.0) | 95.5 (7.5) | 95.1 (7.1) | 100.8 (14.4) | 100.7 (14.0) |
| Blood pressure (mmHg) | ||||||
| Systolic | 129.3 (16.8) | 128.8 (17.0) | 127.1 (16.7) | 126.8 (17.3) | 132.2 (16.4) | 131.3 (16.3) |
| Diastolic | 81.5 (10.6) | 81.0 (10.6) | 82.5 (10.4) | 82.1 (10.6) | 80.1 (10.8) | 79.6 (10.5) |
| HbA1c (mmol/mol) | 43.6 (1.4) | 43.6 (1.4) | 43.5 (1.4) | 43.6 (1.4) | 43.8 (1.4) | 43.8 (1.4) |
| HbA1c (%) | 6.1 (0.1) | 6.1 (0.1) | 6.1 (0.1) | 6.1 (0.1) | 6.2 (0.1) | 6.2 (0.1) |
| Fasting glucose (mmol/l) | 5.5 (0.7) | 5.5 (0.7) | 5.4 (0.7) | 5.4 (0.7) | 5.6 (0.6) | 5.6 (0.6) |
| Lipid profile (mmol/l) | ||||||
| Total cholesterol | 4.9 (1.1) | 4.9 (1.0) | 4.7 (0.9) | 4.7 (0.8) | 5.2 (1.2) | 5.2 (1.2) |
| HDL-cholesterol | 1.2 (0.4) | 1.2 (0.4) | 1.0 (0.2) | 1.0 (0.2) | 1.5 (0.4) | 1.4 (0.4) |
| LDL-cholesterol | 3.0 (0.9) | 3.1 (0.9) | 3.0 (0.8) | 3.0 (0.7) | 3.1 (1.1) | 3.1 (1.1) |
| Triacylglycerols | 1.3 (1.0–1.8) | 1.3 (1.0–1.8) | 1.3 (1.0–1.7) | 1.3 (1.0–1.7) | 1.3 (0.9–1.8) | 1.3 (0.9–1.8) |
Data are mean (SD) or n (%) unless otherwise indicated
aMedian (interquartile range)
Fig. 2Cumulative percentage of individuals with type 2 diabetes at each follow-up visit
Fig. 3Effect of intervention on primary outcome (the development of type 2 diabetes) overall (p = 0.22) and by pre-specified subgroups (intervention × country interaction: p = 0.33; intervention × sex interaction: p = 0.12)
Fig. 4Overall effect of intervention on secondary outcomes (n = 2062). Intervention effects represent differences between intervention and control groups, estimated from a linear regression model with random intercepts at the individual level, using measures of the outcome at all follow-up times, and including baseline value of the outcome, country, randomised group and time (months of follow-up). Intervention effects are presented in units of baseline SD of each outcome. Triacylglycerol results are presented using log-transformed values. MVPA, moderate-to-vigorous physical activity
Secondary outcomes at baseline and follow-up
| Variable | Control | Intervention | ||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | 6 months | 12 months | 24 months | Baseline | 6 months | 12 months | 24 months | |
| HbA1c (mmol/mol) | 43.6 (1.4) | 42.9 (5.2) | 42.5 (5.8) | 43.5 (5.9) | 43.6 (1.4) | 43.1 (4.8) | 42.4 (5.3) | 43.7 (5.2) |
| HbA1c (%) | 6.1 (0.1) | 6.1 (0.5) | 6.0 (0.5) | 6.1 (0.5) | 6.1 (0.1) | 6.1 (0.4) | 6.0 (0.5) | 6.1 (0.5) |
| FPG (mmol/l) | 5.5 (0.7) | 5.6 (0.8) | 5.7 (1.0) | 5.5 (0.7) | 5.7 (0.8) | 5.7 (0.8) | ||
| Weight (kg) | 79.7 (15.6) | 79.4 (15.5) | 78.6 (15.0) | 78.1 (14.9) | 79.0 (15.4) | 78.5 (15.3) | 77.9 (15.1) | 77.4 (14.7) |
| BMI (kg/m2) | 28.9 (4.8) | 28.7 (4.8) | 28.5 (4.6) | 28.3 (4.6) | 28.7 (4.7) | 28.5 (4.5) | 28.4 (4.6) | 28.2 (4.4) |
| WC (cm) | 97.8 (11.3) | 97.1 (11.3) | 96.7 (10.9) | 96.3 (10.8) | 97.5 (11.0) | 96.7 (10.9) | 96.2 (10.7) | 96.2 (10.7) |
| Blood pressure (mmHg) | ||||||||
| Systolic | 129.3 (16.8) | 128.2 (16.8) | 125.1 (15.9) | 124.8 (16.8) | 128.8 (17.0) | 128.4 (17.1) | 125.2 (17.0) | 124.7 (16.1) |
| Diastolic | 81.5 (10.6) | 81.1 (10.4) | 80.3 (10.1) | 79.6 (9.3) | 81.0 (10.6) | 80.7 (10.4) | 79.9 (10.1) | 79.4 (9.1) |
| Lipid profile (mmol/l) | ||||||||
| Cholesterol | 4.9 (1.1) | 5.0 (1.1) | 5.0 (1.0) | 4.9 (1.0) | 5.0 (1.0) | 5.0 (1.0) | ||
| HDL-cholesterol | 1.2 (0.4) | 1.2 (0.4) | 1.2 (0.4) | 1.2 (0.4) | 1.2 (0.4) | 1.2 (0.4) | ||
| LDL-cholesterol | 3.0 (0.9) | 3.0 (0.9) | 3.1 (0.9) | 3.1 (0.9) | 3.1 (0.9) | 3.1 (0.9) | ||
| Triacylglycerols | 1.3 (1.0–1.8) | 1.4 (1.0–1.9) | 1.3 (1.0–1.9) | 1.3 (1.0–1.8) | 1.4 (1.0–1.8) | 1.3 (1.0–1.8) | ||
| Total energy intake (kJ/day) | 8303 (2301) | 7997 (2060) | 7828 (2015) | 7654 (1866) | 8365 (2746) | 7875 (1998) | 7871 (1937) | 7695 (1894) |
| Fat intake (g/day) | 62.9 (26.4) | 59.6 (19.1) | 57.9 (19.7) | 57.4 (17.4) | 63.2 (32.3) | 58.2 (19.3) | 58.9 (20.9) | 57.8 (21.1) |
| Carbohydrates (g/day) | 279.5 (90.5) | 270.9 (90.5) | 266.8 (87.2) | 259.0 (83.8) | 282.2 (99.3) | 265.7 (87.8) | 265.0 (81.9) | 257.8 (75.9) |
| Protein (g/day) | 73.6 (20.2) | 72.1 (18.9) | 70.0 (16.9) | 68.8 (17.1) | 74.9 (23.6) | 72.4 (22.8) | 71.9 (20.1) | 70.8 (26.1) |
| Fibre (g/day) | 24.8 (9.7) | 25.3 (10.3) | 25.1 (9.7) | 25.0 (9.7) | 25.0 (10.0) | 25.0 (10.6) | 25.4 (9.5) | 25.8 (9.4) |
| PAEE (kJ kg−1 day−1), RPAQ | ||||||||
| Total | 48.3 (39.0) | 45.6 (38.0) | 48.6 (36.9) | 47.9 (35.7) | 46.5 (36.2) | 44.2 (35.3) | 47.5 (35.3) | 46.1 (34.6) |
| Home | 2.9 (7.7) | 2.5 (6.0) | 2.4 (6.1) | 2.7 (8.4) | 3.1 (9.1) | 2.5 (6.6) | 2.7 (6.7) | 2.3 (5.4) |
| Work | 31.3 (26.2) | 31.6 (26.5) | 31.8 (26.6) | 31.3 (26.0) | 32.2 (25.6) | 32.1 (26.0) | 32.8 (26.4) | 32.3 (26.1) |
| Commuting | 11.7 (20.7) | 11.3 (20.3) | 12.1 (21.0) | 12.1 (21.1) | 9.4 (17.6) | 9.4 (17.6) | 9.4 (17.6) | 9.7 (18.0) |
| Leisure | 11.7 (17.1) | 12.0 (15.3) | 11.7 (13.4) | 10.7 (11.9) | 11.6 (14.9) | 12.0 (13.2) | 11.8 (13.2) | 10.9 (11.7) |
| Physical activity, ActiGraph | ||||||||
| Total physical activity (counts/min) | 412.2 (122.5) | 403.7 (126.8) | 433.8 (132.0) | 400.9 (125.5) | 409.0 (127.6) | 405.5 (129.5) | 439.1 (136.4) | 396.5 (124.7) |
| Time spent in MVPA (h) | 1.7 (0.7) | 1.7 (0.6) | 1.8 (0.7) | 1.7 (0.7) | 1.7 (0.7) | 1.7 (0.7) | 1.8 (0.7) | 1.6 (0.7) |
| Time spent in sedentary activity (h) | 18.6 (1.3) | 18.8 (1.3) | 18.3 (1.4) | 18.8 (1.3) | 18.7 (1.3) | 18.7 (1.3) | 18.3 (1.4) | 18.8 (1.3) |
| EQ-5D-3L summary measure | 0.95 (0.10) | 0.94 (0.10) | 0.94 (0.10) | 0.93 (0.11) | 0.94 (0.11) | 0.94 (0.10) | 0.93 (0.11) | 0.93 (0.11) |
| Body fat (%)a | 31.2 (5.7) | 30.8 (5.7) | 31.1 (5.7) | 30.9 (5.8) | 31.0 (5.3) | 31.0 (5.4) | 31.2 (5.3) | 30.9 (5.5) |
| HOMA-IRa | 2.8 (1.9–4.0) | 3.2 (2.2–4.6) | 3.0 (2.1–4.4) | 2.8 (1.8–4.2) | 3.2 (2.2–4.5) | 3.2 (2.1–4.4) | ||
| HOMA-Ba | 138.9 (90.0–206.5) | 131.3 (86.6–194.3) | 123.5 (86.0–165.6) | 135.9 (85.0–199.9) | 124.7 (84.6–191.0) | 127.7 (80.9–182.9) | ||
Data are mean (SD) or median (interquartile range)
aOnly measured in India (n = 1171)
FPG, fasting plasma glucose; WC, waist circumference; MVPA, moderate-to-vigorous physical activity